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Background: Numerous transgenic models have been generated to study breast cancer. However, despite many
advantages, traditional transgenic models for breast cancer are also burdened with difficulties in early detection and
longitudinal observation of transgene-induced tumours, which in most cases are randomly located and occur at
various time points. Methods such as palpation followed by mechanical measurement of the tumours are of limited
value in transgenic models. There is a crucial need for making these previously generated models suitable for
modern methods of tumour visualisation and monitoring, e.g. by bioluminescence-based techniques. This approach
was successfully used in the current study.
Results: A new mouse strain (MMTV-Luc2 mice) expressing Luc2 luciferase primarily in mammary tissue in females,
with low-level background expression in internal organs, was generated and bred to homozygosity. After these
mice were intercrossed with MMTV-PyVT mice, all double transgenic females developed mammary tumours by the
age of 10 weeks, the localisation and progression of which could be effectively monitored using the luminescence-
based in vivo imaging. Luminescence-based readout allowed for early visualisation of the locally overgrown
mammary tissue and for longitudinal evaluation of local progression of the tumours. When sampled ex vivo at the
age of 10 weeks, all tumours derived from MMTV-Luc2PyVT females displayed robust bioluminescent signal.
Conclusions: We have created a novel transgenic strain for visualisation and longitudinal monitoring of mammary
tumour development in transgenic mice as an addition and/or a new and more advanced alternative to manual
methods. Generation of this mouse strain is vital for making many of the existing mammary tumour transgenic
models applicable for in vivo imaging techniques.
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Transgenic cancer models are invaluable research tools
because they recapitulate the entire process from the ini-
tial genetic events in normal cells to metastatic disease.
Therefore, transgenic mice are ideally suited for studies
on the role of oncogenes in carcinogenesis and on the
progression of the tumours to invasion and metastasis.
Transgenes can be induced to express in the mouse
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distribution, and reproduction in any mediumpromoters, such as MMTV-LTR, WAP, C(3)1 and BLG,
which have particular characteristics in expression pat-
terns and other biological aspects. Among these, mouse
mammary tumour virus promoter/enhancer (MMTV-
LTR) has been most used (reviewed in [1]), since this
promoter provides expression of a gene of interest in the
mammary epithelium in both non-lactating and lactating
females. In the last three decades, numerous transgenic
mouse models of breast cancer have been generated by
manipulating growth factors and their receptors, as well
as cell cycle regulators and other signal transduction
mediators. For instance, the MMTV promoter has been
used for expression in transgenic animals of varioustral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cyclin D1 [5], Ras [6] or Myc [7]. These molecules have
been selected based on the fact that their genes or their
products are frequently altered in human breast cancers
and studies in these models produced relevant results for
breast cancer research. One of the classical transgenic
models for breast cancer development involved the
mammary gland-specific expression of the polyomavirus
middle T antigen (PyVT) expressed under the transcrip-
tional control of the MMTV promoter [8]. In this
model, expression of the PyVT oncogene in the breast
induced widespread transformation of the mammary
epithelium and rapid development of multifocal mammary
adenocarcinomas.
Despite the advantages of animal transgenic models
for breast cancer, these models are also burdened with
certain shortcomings. One of the major obstacles in
studies involving transgenic models are problems asso-
ciated with early detection and monitoring of transgene-
induced tumours, which in most cases are randomly
located and occur at various time points. Methods such
as palpation followed by mechanical measurement of the
tumour using callipers are of limited value in transgenic
models, although such attempts have been undertaken
[9,10]. Theoretically, these difficulties can be overcome
by the use of advanced whole-body imaging techniques
such as microCT, MRI, PET or SPECT. However, such
techniques are laborious, considerably expensive and/or
raise significant safety issues. Conversely, non-invasive
optical imaging appears to be a feasible and safe alterna-
tive to the radiation-based imaging techniques (reviewed
in [11-13]). Indeed, introduction of advanced optical
imaging techniques for in vivo imaging of tumour growth
and progression in animal models have revolutionised
in vivo cancer studies.
Optical imaging systems have conventionally played a
significant role in molecular imaging of gene reporters,
molecular targets and receptors in preclinical studies of
cancer. The availability of tomographic techniques has fur-
ther advanced the use of in vivo optical imaging systems.
Optical imaging agents are typically either bioluminescent
or fluorescent in their nature. Currently, bioluminescence
readout from cells expressing firefly luciferase is regarded
the most sensitive system for optical imaging, especially
after the recent development of the next-generation en-
hancement of firefly luciferase, namely Luc2 [14]. Hence,
dramatic progress has been made in visualising different
kinds of transplanted tumour tissues in both syngeneic
and xenotransplantation models. Nevertheless, generation
of transgenic tumour models which are ‘compatible’ with
bioluminescence-based imaging is hampered by the neces-
sity for dual expression of both the transgene and the
luciferase gene in the tissue of interest. For newly gener-
ated models, this can be successfully achieved on a case-by-case basis via the use of bicistronic vectors in which
cDNA of the transgene is followed by an IRES sequence
and then by the cDNA for luciferase [15-17]. However,
luciferase expression from bicistronic vectors is a reporter
for the particular transgene expression rather than a marker
of the ‘specific tissue content’ and, as such, should be used
with caution for visualisation of the transgene-induced
overgrowth of the malignant tissue. That especially holds
true, if mice bearing ‘promoter-oncogene-IRES-luciferase’
transgene are intercrossed with another genetically
modified strain. Also, markers for the ‘tissue content’
rather than the oncogenic transgene expression are more
suitable, when the ‘oncogene’ acts in a paracrine manner
and mammary tumours can be subsequently formed from
the cells induced by the ‘oncogene’, but not expressing the
‘oncogene’ construct themselves. Moreover, vectors en-
coding ‘imageable’ molecules are unlikely to be introduced
by direct genetic manipulation (e.g. microinjection) into
already existing transgenic models, expressing only the
oncogenic transgene under a tissue-specific promoter,
such as MMTV-PyVT mice. Nevertheless, such models
can still be rendered ‘imageable’, if interbred with another
mouse strain already expressing an ‘imageable’ molecule
under the same type of the promoter. Thus, the gener-
ation of such a mouse strain is vital for making many of
the existing mammary tumour transgenic models applicable
for advanced in vivo imaging techniques. In our project, we
have generated a mouse strain expressing an enhanced
firefly luciferase under a breast tissue-specific promoter
and we present data documenting that it can be utilised as
a new bioluminescent model for visualisation of mammary
tumour development in transgenic mice.
Materials and methods
Generation of the MMTV-Luc2 transgenic construct
The pGL4.10[luc2] vector was purchased from Promega
Corp. (Madison, WI). A MMTV-cFos-SV40 construct
(Addgene plasmid 19259) was obtained from Dr. Philip
Leder via Addgene Inc. (Cambridge, MA). The original
cFos cDNA was replaced by Luc2 cDNA within the
MMTV-SV40 construct using HindIII and XbaI (both
enzymes from NEB, Ipswich, MA) digest, followed by T4
ligation (Promega). Prior to microinjection, the construct
has been linearised by digestion with SpeI and SalI (NEB)
enzymes, run on a 0.8% agarose gel with crystal violet,
extracted from the gel via a Qiaex II gel extraction
kit (Qiagen Inc., Valencia, CA), and then resuspended
at a concentration of 1.2 ng/μl in EmbryoMax Injection
Buffer (Millipore, Billerica, MA). In order to generate
MMTV-Luc2 transgenic animals, pronuclear injections
of the fertilised oocytes and embryo transfer to the
pseudopregnant females was carried out within the UCD
Conway Institute Biotechnical Services (CIBS) facility.
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Additional file 1). Sequences of the primers used for geno-
typing of the MMTV-Luc2 mice are as follows: forward
primer, 5’-ACAGAAACAACCAGCGCCATTCTG-3’; re-
verse primer, 5’-TCCAACTTGCCGGTCAGTCCTTTA-
3’ (please see Additional file 1).Mice Wild-type FVB/N mice and FVB/N-Tg(MMTV-
PyVT)643Mul/J (MGI:2679595; further referred to as
MMTV-PyVT mice) were purchased from Charles River
UK (Margate, Kent, UK) and Jackson Laboratories (Bar
Harbor, Maine), respectively. Mice were maintained and
bred within the UCD CIBS and UCD Biomedical facil-
ities under specific pathogen free (SPF) conditions with
unrestricted access to food and drinking water. All pro-
tocols involving animals have been approved by UCD
Animal Research Ethics Committee and carried out under
the licence No. B100/4283 from the Irish Department
of Health & Children. All transgenic work has been
registered with the Environmental Protection Agency of
Ireland (reg. No. G0310-01).Whole animal and ex vivo imaging MMTV-Luc2
(heterozygous or homozygous) animals or double trans-
genic MMTV-Luc2 x MMTV-PyVT (both transgenes
heterozygous, further referred to as MMTV-Luc2PyVT)
animals were used for luciferase assay studies. All females
subjected to imaging in this study were nulliparous. Prior
to in vivo imaging, mice received intraperitoneal adminis-
tration of luciferin in Dulbecco's Phosphate Buffered
Saline (final dose of 150 mg/kg mouse body weight).



















Figure 1 Generation and bioluminescent imaging of MMTV-Luc2 mice.
MMTV-Luc2 mice. (B) Whole-body luminescent imaging of representative n
female founders with wild-type FVB/N males. MMTV-Luc2 sub-strain #3 (arr
5: numbers of the respective sub-strains (please refer to Additional file 1 Fi
indication of embryonic lethality during transgene vertical transmission stuimaged using an IVIS Spectrum system (Caliper Life
Sciences, Hopkinton, MA) to visualise luciferase-expressing
tissues. In relation to imaging of non-oncogene-bearing
animals, F/STOP parameter value 1 was used. In experi-
ments with oncogene-bearing mice, F/STOP 2 was used
for both oncogene-bearing and non-oncogene-bearing
littermates. For ex vivo imaging, mice were injected
with luciferin and imaged as stated above, subjected to
euthanasia by cervical dislocation while under anaesthesia,
and then internal organs or tumours were isolated and
visualised by the IVIS Spectrum system. Imaging data
were analysed using Living Image 3.2 software (Caliper).
DLIT™ algorithm was used for 3D reconstitution.Statistical analysis Prism 5 (GraphPad Software Inc, La
Jolla, CA) software was used for statistical analysis, unless
otherwise stated. Differences between the experimental
groups in respect to total luminescent imaging during first
measurement of whole body readout were analysed by a
two-tailed unpaired Student’s t test (MS Excel 2007,
Microsoft, Redmond, WA). Correlation between whole
animal luminescent readout and tumour palpation was
analysed using a Spearman correlation and linear regres-
sion curve fit tests. Difference in tumour-free survival
between MMTV-Luc2het and MMTV-Luc2PyVT females
was analysed by Gehan-Breslow-Wilcoxon test. Results
were considered to be statistically significant at p< 0.05.Results
Identification of transgenic founders and generation
of homozygous mice Following microinjections of theMTV-Luc2 sub-strain #
5  4 3   1
(A) Schematic of the transgenic construct used for generation of
ulliparous F1 females from sub-strains obtained by crosses of F0
ow) was selected for further studies. Wild-type: FVB/N female; 1, 3, 4,
gure S1). [Note: strain #2 was discontinued prior to imaging because of
dies].
Zagozdzon et al. BMC Cancer 2012, 12:209 Page 4 of 10
http://www.biomedcentral.com/1471-2407/12/209linearised transgene (Figure 1A) into fertilized oocytes
and embryo transfer to pseudopregnant females, 35 pups
were obtained. Ten of the pups were strongly positive
for transgene presence in their genomic DNA, as
assessed by PCR amplification (Additional file 1 Figure
S1). Out of these, five females were chosen as potential
founders (numbered #1-5) and crossed with wild-type
FVB mice in order to assess germline transmission of
the transgene. In case of founder #2, the percentage of
transgene-positive offspring was markedly below the
expected 50% Mendelian distribution, which suggested
embryonic lethality, and thus the sub-strain #2 was dis-
continued. From the remaining four sub-strains, randomly
chosen MMTV-Luc2-positive heterozygous females were
subjected to whole animal luminescent imaging. As shown
in Figure 1B, only one (#3) out of four imaged sub-strains
presented clear mammary tissue-specific distribution of
the luminescent signal. This sub-strain was selected for
further interrogations. Another sub-strain (#5) showed
low-level generalised skin luminescence, which was below
the detection threshold under imaging conditions used in
Figure 1B. Sub-strains #1 and #4 did not produce detect-
able luminescent signals via whole body luminescent
imaging.
Additional file 1 Figure S2 demonstrates luminescent
signal distribution within representative heterozygous
mice from the MMTV-Luc2 #3 sub-strain (hereafter re-
ferred to as the ‘MMTV-Luc2’ strain). Using non-invasive
whole animal imaging (Figure 1B and Additional file 1
Figure S2), potent luminescence could be mainly seen in
areas corresponding to the distribution of mammary
tissue in females. Notably, regions corresponding to lo-
calisation of salivary glands were also strongly positive
for luminescence, which is a classical distribution for
MMTV-driven expression of the transgene [18,19].
After isolation of the internal organs (Figure 1D), lumi-
nescent signal of markedly lower magnitude was
detected mainly from the spleen, lungs, thymus, and
liver, as well as kidneys and intestine (Additional file 1
Figure S2). As expected, no gross alterations regarding
breeding, mouse behaviour or anatomical parameters
were observed in MMTV-Luc2 animals as compared to
the wild-type littermates.
It must be stated, however, that heterozygous MMTV-
Luc2 (MMTV-Luc2het) females presented noticeable
variability in the strength and distribution of luminescent
signal, as determined by non-invasive whole animal
imaging (see below). Therefore, by intercrossing the
MMTV-Luc2het females and males, we have generated
homozygous MMTV-Luc2 animals and used them for fur-
ther breeding and maintenance of the strain. Again, no
gross alterations were observed in homozygous MMTV-
Luc2 animals. As shown in Additional file 1 Figure S3,
homozygous females and males presented relativelyuniform luciferase expression patterns as well as similar
potency in respect to luminescence signal, as assessed
by non-invasive whole animal imaging. More detailed
representation of the luminescent signal distribution in
the in vivo and ex vivo imaging of representative
homozygous MMTV-Luc2 females is shown in Figure 2
and Additional file 1 Figure S4A-C,E,F. Figure 2E shows
a 3-dimensional tomographic reconstitution of the signal
distribution in a representative homozygous MMTV-Luc2
female. Whole body autopsy (Figure 2B) showed that the
source of the signal from mammary gland regions was, as
expected, subcutaneous, with the non-specific signal from
the internal organs remaining below detection range
under this exposure setting. Potent signal could be
detected from isolated salivary glands (Figure 2C). After
isolation of the internal organs (Figure 2D), luminescent
signal of markedly lower magnitude was again detected
mainly from the spleen, lungs, kidneys and intestine.
Interestingly, the mouse intestine is capable of producing
bioluminescent signal due to processes of digestion. In
this study, we have specifically addressed the issue of in-
testinal luminescence by carrying out imaging of intestines
isolated from a representative MMTV-Luc2 homozygous
mouse without prior injection of luciferin. As shown in
the revised Additional file 1 Figure S5, a low level lumi-
nescence was detected, which then increased roughly 10-
fold after soaking the intestine with luciferin solution.
That confirms the presence of spontaneous intestinal bio-
luminescence, but also suggests that the Luc2 transgene
was also expressed in the intestine, most probably in the
intestinal immune tissue, similar to the expression
detected in the spleen. Nonetheless, as the background
signal from internal organs, including intestine was negli-
gible when compared to the potent signal from salivary
and mammary glands (Figures 2B-D), which was further
dramatically amplified in developing tumours (see below),
we do not find maintenance of MMTV-Luc2 mice on a
specialised diet necessary.
Also, according to the blinded pathological assessment,
there was no evidence of histological alterations in mam-
mary gland structure in the homozygous MMTV-Luc2
versus age-matched control mice, with both of them
showing normal mammary gland growth and develop-
ment (Additional file 1 Figure S4D).
Monitoring of the mammary tumour development
Having established the MMTV-Luc2 strain, we assessed its
utility as a tool for monitoring of mammary tumour devel-
opment and progression in oncogene-bearing transgenic
mice. To this end, homozygous MMTV-Luc2 females were
interbred with MMTV-PyVT heterozygous males. Among
31 littermates from these crosses, 16 pups were identified
by PCR as MMTV-Luc2het, with the remaining 15 identi-












Figure 2 Imaging of a representative nulliparous homozygous MMTV-Luc2 female mouse. [Note: A-D images were obtained from the same
representative female; please refer to Additional file 1 Figures S3 and S4 for additional examples] (A) Distribution of bioluminescent signal via
whole body imaging. (B) Distribution of bioluminescent signal in whole-body autopsy. (C) Imaging of the isolated salivary glands. (D) Distribution
of bioluminescent signal in isolated internal organs. B: brain, H: heart, Int: intestine, K: kidney, Lg: lungs, Lv: liver, S: spleen. [Please note that the
ranges of the luminescence readout between panels A and D are 100-fold different, as shown by the colour bar scales]. (E) Tomographic DLIT™
3D reconstitution of the luminescent signal distribution [29] at the wavelength of 660 nm from a representative homozygous MMTV-Luc2 female
(ventral view). Reconstituted sources of luminescent light are shown as spheres (please note a superficial localisation of the light sources). Left-
hand panels represent slices acquired by slice planes shown on the right hand panel: coronal (red), sagittal (blue) and transaxial (green).
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invasive whole body luminescent imaging between the ages
of 5 up to 10 weeks. The age of each animal at the time
of each measurement was approximated to full weeks
(median age at the time of the first measurement was
35 days, range 34-38 days). Simultaneously, mammary
tumour development was monitored in mice by observa-
tion and palpation. As shown in Figure 3A, all PyVT-
bearing mice developed palpable tumours by the age of
10 weeks, which corresponds to the described phenotype
of the MMTV-PyVT transgenic strain [8,19]. No tumours
were detected in MMTV-Luc2het animals throughout the
experiment. During the initial luminescent imaging at
5 weeks of age, the MMTV-Luc2het control animals
presented with variable distribution and potency of
luminescent signal (Additional file 1 Figure S6A).
Conversely, virtually all MMTV-Luc2PyVT littermates
have shown foci of potent luminescent signal, which
correlated with the localisation of mammary tissue and
indicated regional pre-malignant or early malignant
overgrowth of mammary epithelium in these spots
(Additional file 1 Figure S6B and C), while, notably,
none of the animals within the experiment produced a
palpable tumour by the age of 5 weeks. On average, total
body luminescence from the MMTV-Luc2PyVT animals
during the first measurement exceeded that from con-
trol MMTV-Luc2het mice by 21.01-fold (Figure 3B,
p=0.003 at 5-week time point). The mean total body lumi-
nescent readout from MMTV-Luc2PyVT mice increased
exponentially in subsequent weeks (Figure 3B and 3C;
please note the log2 scale of the Y axis in Figure 3B),
whereas the readout from MMTV-Luc2het controls did
not show tendency to increase with age. Importantly, there
was a significant inverse correlation between the potency of
the first luminescent total body readout and the age of the
first palpable tumour development in MMTV-Luc2PyVT
mice, i.e. mice with higher luminescent signal at the age of
5 weeks tended to develop palpable tumours sooner in the
following weeks (Figure 3D). To evaluate the ability of
individual tumours to produce luminescent light, three
MMTV-Luc2PyVT mice were randomly selected at the
end of the experiment for post mortem isolation of
tumours for ex vivo imaging. As shown in Figure 3E
and Additional file 1 Figure S7A, all isolated tumours pro-
duced detectable luminescent signal, although variable in
its potency. This observation corresponds to the previ-
ously reported phenomenon of variable expression of
MMTV promoter-driven transgenes across mammary
epithelium [19]. In histological evaluation, the tumours
were classified, as expected, as adenocarcinomas, malignant
tumours of glandular epithelium (Additional file 1 Figure
S7B). This corresponds with pathological observations from
the initial publication regarding the MMTV-PyVT mouse
model [8].Discussion
In this work, we report successful generation of a new
transgenic mouse strain expressing an enhanced form of
firefly luciferase (Luc2) in a mammary tissue-specific
manner. We also report successful application of this
new strain for visualisation of primary tumour develop-
ment and longitudinal monitoring of local tumour pro-
gression in oncogene-bearing transgenic animals.
Improvement of currently existing transgenic animal
models for breast cancer is a pressing issue and has been
addressed by different approaches in the past. Conceptually,
MMTV-Luc2 mouse model stands in line with previously
generated models of luciferase expression driven by other
tissue-specific promoters, which are currently available
from Taconic Farms, Inc. (Hudson, NY). These models
include such strains as FVB/N-Tg(Vegfr2-luc)-Xen
(vascular-specific expression [20]) or FVB/N-EL1-Luc/
EL1-Tag (pancreatic expression).
Theoretically, another strain available from Taconic, the
LucRep (FVB) mice [21], can be engineered for mammary
tissue-specific expression using a Cre-activated system
[22]. It has been previously shown that Cre-activated
luminescence permits, for instance, a temporally and
spatially controlled expression of responder genes in
embryonic and multiple adult tissues [23]. Therefore,
from a mechanistic perspective, using a Cre-activated sys-
tem would provide decreased variability of the model sys-
tem as compared to MMTV-driven expression. It must be
considered, however, that Cre-activated luminescence
brings the need for using yet another mouse strain (e.g.
WAP-Cre [22]) within the crossbreeding schedule.
Conversely, one of the strengths of the MMTV-Luc2
mice lies in the increased feasibility of this system over
Cre-activated models; indeed, the MMTV-Luc2 model
could be found desirable for some transgenic projects,
especially ones utilising non-Cre-activated oncogenic
strains, such as MMTV-PyVT. It is also important to
mention that using the Cre-activated system can also
lead to mosaic expression profile in some instances [19].
In summary, while certain advantages of Cre-activated
systems are obvious, MMTV-Luc2 mice can provide a
practical alternative to these models. ODD-luciferase mice
[24,25] are another universal strain with potential use for
imaging of mammary tumours in transgenic animals. In
this model, expression of luciferase is induced by hypoxic
conditions within tumours. However, in vivo imaging in
ODD-luciferase strain has shown significant generalised
background luminescence of the body [25], as hypoxia
is intrinsic in some tissues under normal conditions,
which can hamper exact localising of early overgrowth
of mammary tissue via in vivo imaging. Notably, this
task can be successfully achieved by the use of
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E
Figure 3 Evaluation of development and progression of spontaneous mammary tumours in MMTV-Luc2PyVT mice versus MMTV-Luc2het
controls. (A) Evaluation of tumour development by palpation in double heterozygous MMTV-Luc2PyVT female mice versus MMTV-Luc2het
females. (B) Evaluation of the total body luminescent signal in MMTV-Luc2PyVT female mice versus MMTV-Luc2het females between 5-10 weeks
of age. Points: mean values + standard deviations (C) Longitudinal observation of the localisation and intensity of luminescent signal in a
representative MMTV-Luc2PyVT female between 5-10 weeks of age. (D) Correlation between the intensity of total body luminescence readout at
5 weeks of age and the age of development of the first palpable tumour in MMTV-Luc2PyVT female mice. Line: linear regression curve fit
(r2 = 0.4759; p = 0.0044) (E) Ex vivo luminescent imaging of mammary tumours isolated from the representative MMTV-Luc2PyVT female [shown
in panel (C)] at the age of 10 weeks.
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previously generated MMTV- or WAP- GFP mice, which
are mouse strains expressing green fluorescent protein
(GFP) under various mammary tissue-specific promoters
[19]. GFP-based imaging has been also successfully used
for longitudinal studies of mammogenesis [26]. However,
although successfully generated, the applicability of GFP-
based systems is of very limited value for whole animal
in vivo imaging, mainly because of autofluorescence-related problems and low tissue penetration of the light
emitted by GFP. Conversely, detection of bioluminescence
from cells expressing firefly luciferase is considered the
most sensitive technique for optical imaging in vivo [11],
as light produced after the reaction catalysed by luciferase
penetrates the tissues with high efficacy. The issue of auto-
fluorescence is also alleviated, as bioluminescence does
not require the excitation light. Hence, our model holds
substantial advantages over GFP-based systems.
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by design is not expected to be capable of detecting me-
tastases (e.g. into the lungs) directly in living transgenic
animals, primarily because of the robust localisation of
mammary tissue in female mice. In result, the background
signal from superficially located mammary tumours and
also healthy mammary tissue would set up the imaging
threshold too high for potential detection of metastases in
whole body imaging in vivo. Therefore, we wish to recom-
mend the usage of the MMTV-Luc2 mice mainly for
monitoring the growth of primary tumours, at least with
the currently available bioluminescent imaging systems.
Another issue related to the applicability of the MMTV-
Luc2 model system is the evidence from previous studies
that the MMTV-driven expression of the transgene is pri-
marily active in luminal epithelial cells rather than basal
cells in the gland (reviewed in [27]). Therefore, while
MMTV-Luc2 mice appear relevant for imaging of other
MMTV-driven oncogenic model systems, as exemplified
by the MMTVPyVT model in this work, the applicability
of MMTV-Luc2 imaging in basal-type breast cancer
models (such as BRCA1-knockout mice [28]) is yet to be
studied.
As mentioned above, the MMTV-Luc2 model has been
primarily designed for rendering the currently available
MMTV-oncogene-based strains applicable for advanced
luminescent imaging. Such enhancement greatly increases
the capability of monitoring local tumour development
and progression, but potentially also response to therapies
in such models. We present an example of such an appli-
cation by intercrossing the MMTV-Luc2 mice with the
MMTV-PyVT strain. However, what must be mentioned
is that luciferase-based quantification of the signal is not
primarily designed to not be used for direct quantification
of the tumour burden in living animals, but rather as an
indicative marker. One of the reasons for this fact is the
well established phenomenon of mosaic expression of the
MMTV-driven transgene, especially in heterozygous
animals. Indeed, in the MMTV-Luc2 model, we do see
some differences in production of the luminescent signal
among the tumours taken out from the MMTV-Luc2PyVT
females (Figure 3E and Additional file 1 Figure S7A).
Secondly, MMTV promoter activation is known to be
modulated by steroid and peptide hormones that, in
turn, can alter a linear correlation between cell number
and the potency of luciferase signal. Therefore, we
would like to recommend the MMTV-Luc2 imaging as
supportive tool to manual methods of tumour monitoring.
At the same time, we would like to strongly point out that
homozygous MMTV-Luc2 females express a much more
unified pattern of luminescent signal considering the
promoter being used, which indicates they can be feasibly
applicable for tumour visualisation purposes in transgenic
models for breast cancer.For future applications, as the MMTV-Luc2 homozygous
mice are viable and fertile, this strain can be also used
instead of wild-type FVB mice as a primary strain for
generating new models incorporating mammary tissue-
specific expression of a molecule of choice. Ideally,
bicistronic vectors encoding the molecule of interest
(most frequently a putative oncogene) and fluorescent
markers (to highlight oncogenic transgene expression)
would be introduced into MMTV-Luc2 mice and then
visualised in a dual-modality manner for co-localisation
of fluorescence and luminescence. This would provide
information on both levels of transgene expression (by
fluorescence) and potential local changes in mammary
tissue ‘content’ (by luminescence) in these new models.
Importantly, the use of the homozygous MMTV-Luc2 mice
in such systems will decrease the intra-strain variability of
tissue-specific Luc2 expression in comparison to imaging of
heterozygous MMTV-Luc2 mice. This, in turn, would cor-
respond to the current ethical considerations regarding
studies involving animals, i.e. our model will facilitate
reduction in the number of transgenic animals per group
necessary for obtaining statistically significant results.
Conclusions
In summary, our project has provided a novel transgenic
strain for early detection and monitoring of mammary
tumour development in transgenic mice. Generation of
this mouse strain is vital for making many of the existing
mammary tumour transgenic models applicable for
advanced in vivo imaging techniques. It can also serve
as a technology platform and a background strain for
further development of new models.
Additional file
Additional file 1: Figure S1. Identification of potential founders from F0
pups born after microinjections of MMTV-Luc2 construct. Ten mice (blue
arrows) were identified by PCR as positive for transgene presence, and five
females (green arrows) were selected as potential founders of the MMTV-Luc2
sub-strains #1-5. DNA marker used: 2-Log DNA Ladder (0.1–10.0 kb) (NEB).
Figure S2. Whole-body luminescent imaging (upper panels) and ex vivo
imaging of isolated internal organs (lower panels) of three representative
MMTV-Luc2het virgin females. B: brain, H: heart, Int: intestine, K: kidney, Lg:
lungs, Lv: liver, S: spleen, Th: thymus. Figure S3. Distribution of luminescent
signal from whole-body imaging of homozygous MMTV-Luc2 littermates. (A)
virgin females; (B) males. Mice were of 101 days of age at the time of imaging.
Figure S4. Presentation of a representative homozygous MMTV-Luc2 virgin
female (A) Distribution of luminescent signal in a whole-body imaging; (B) ex-
vivo whole body necropsy; (C) ex vivo imaging of isolated internal organs; B:
brain, H: heart, Int: intestine, K: kidney, Lg: lungs, Lv: liver, S: spleen, Th: thymus;
(D) representative histological image of the mammary gland of MMTV-Luc2
virgin female. Haematoxylin and eosin stained section of mammary tissue
revealing randomly dispersed solitary variable-sized ductular structures
embedded in adipose tissue (Bar= 100 μm). (E) and (F) Tomographic surface
reconstitution of the luminescent signal from a representative homozygous
MMTV-Luc2 female from ventral and dorsal views, respectively. Figure S5.
Imaging of the intestine from a representative homozygous MMTV-Luc2
female mouse. The intestine was isolated without prior injection of the
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http://www.biomedcentral.com/1471-2407/12/209luciferin solution to the mouse, 3 therefore the left panel represents
spontaneous luminescent signal from the intestine. Then, luciferin
solution (300 μg/ml) was applied in drops on the isolated organ and
imaging was repeated (right panel). Figure S6. Localisation of the
luminescent signal in the whole-body luminescent imaging of F1 females
from crosses between homozygous MMTV-Luc2 females and MMTV-
PyVThet males. (A) MMTV-Luc2het females (B) Double transgenic and
double heterozygous MMTV-Luc2PyVT females. [Note: in panels (A) and
(B) mice were imaged for one second and the automatic imaging colour
scale adjustments provided by the IVIS Spectrum system were used. The
colour bars were removed for the sake of clarity of the figure.] (C) Image
obtained with mouse number 27 after setting the exposure time to 20
sec. Figure S7. (A) Whole-body (upper panels) and ex vivo luminescent
imaging of mammary tumours (lower panels) isolated from two
representative MMTV-Luc2PyVT females at the age of 10 weeks. (B)
Histopathological assessment showing evidence of mammary
adenocarcinoma formation in a representative MMTV-Luc2PyVT female at
the age of 10 weeks. Haematoxylin and eosin stained sections of
mammary tumour revealing a multinodular densely cellular mass with
cells arranged in sheets and acinar patterns. Increased magnification
reveals moderate cell pleomorphism, prominent mitosis and acinar
structure formations. (Left-hand image – Bar=500 μm; right-hand image –
Bar=25 μm).
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